// App-Quantinova.ai

9574 : Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.

Researchers

Presenter

  • Reinhard Dummer

Principal Investigators

  • Mario Santinami

  • Victoria Atkinson

  • Mario Mandala

  • Vanna Chiarion-Sileni

  • James M. G. Larkin

  • Marta Nyakas

  • Caroline Dutriaux

  • Andrew Mark Haydon

  • Caroline Robert

  • Dirk Schadendorf

  • Paola Aimone

  • Bijoyesh Mookerjee

  • Catarina D. Campbell

  • James Garrett

  • Jan C. Brase

  • Richard Kefford

  • John M. Kirkwood

  • Georgina V. Long

Medical Centers

  • University Hospital Zurich Skin Cancer Center, Zurich, Switzerland

  • University Hospital Schleswig-Holstein, Lubeck, Germany

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Qld, Australia

  • Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

  • Melanoma Oncology Unit, Veneto Oncology Institute, Padova, Italy

  • The Royal Marsden Hospital, London, United Kingdom

  • Oslo University Hospital - The Radiumhospital, Oslo, Norway

  • Centre Hospitalier Universitaire de Bordeaux, Hopital Saint-Andre, Bordeaux, France

  • The Alfred Hospital, Melbourne, Australia

  • Institut Gustave Roussy, Nantes, France

  • University Hospital of Essen, Essen, Germany

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Macquarie University, Melanoma Institute Australia, Westmead Hospital, and The University of Sydney, Sydney, Australia

  • University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA

  • Melanoma Institute Australia, the University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, Australia

Locations

  • Italy

  • Norway

  • Germany

  • Switzerland

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Circulating DNA

Drug/Treatment

  • Dabrafenib Mesylate

  • Trametinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT01682083

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved